Value creation archetypes, part 4: Re-underwritten

Published on September 6, 2026

The Re-Underwritten Value Creation Plan

Resetting the growth engine for extended private equity ownership

Continuation vehicles and long-hold assets are redefining the meaning of value creation in private equity. When capital is recommitted and ownership horizons extend, the logic of value creation must change simultaneously. Simply allowing time to pass, or continuing to run a legacy value creation plan, rarely produces incremental value. In many cases, it accelerates organizational fatigue and erodes momentum.

The Re-…

Value creation in private equity

Continue reading on website
Other news

The pricing–access split: when one model doesn’t fit all

September 4, 2026
td {padding: 10px;}.text-align-center {text-align: center;}As pricing and market access decisions become more interconnected across markets and lifecycle stages, the way these functions are organized matters more than ever. This article explores the two dominant organizational models in life sciences, the trade-offs each brings, and why governance, accountability, and portfolio complexity should s

MFN as a stress test for pharma price governance

October 2, 2026
External price referencing is re-entering the US debate, but its implications extend far beyond policy mechanics. Most Favored Nation (MFN) proposals can directly link US and ex-US drug prices, creating new cross-market risks that directly affect US revenue. For pharma leaders, it can serve as a catalyst to stress test global pricing governance across list, net, and realized metrics.MFN policy: Th